AML patients with higher risk scores were predicted to exert a worse sensitivity against anti-tumor agents including Midostaurin (an FLT3 inhibitor), ABT-263 (a BCL-2 inhibitor), Bleomycin, Bosutinib, and Lenalidomide. The gene discussed is FLT3; the disease is acute myeloid leukemia.